Lawyers USA has ceased publication. If you have purchased a research pass or still have additional time on your current Digital Subscription, you may access locked stories by logging in.
First Neurontin trial begins
Plaintiffs’ lawyer attacks off-label marketing
BOSTON - Addressing jurors in the first Neurontin suicide trial, plaintiffs' lawyer Mark Lanier asserted that drug maker Pfizer knew the anti-epilepsy medication increased the risk of suicide, but intentionally marketed off-label uses to boost the drug's sales.